Hrvatska nogometna reprezentacija okuplja se pred završne nastupe u Ligi nacija, protiv Škotske u Glasgowu 15. studenoga, odnosno protiv Portugala 18. studenoga u Splitu.

Konferenciju za medije tradicionalno je na dan okupljanja održao izbornik Vatrenih, Zlatko Dalić.

“Pred nama su dvije zadnje utakmice u Ligi nacija, Škotska i Portugal. Najvažnija nam je prva, protivnik koji je posljednjeplasirani na ljestvici, ali sve što je izgubio je teško izgubio, imali smo s njima puno problema u Zagrebu. Čvrsti su i disciplinirani, zadnja utakmica protiv Portugala završila je 0:0. Očekujem tešku utakmicu, vrlo važnu jer želimo prije Portugala riješiti pitanje prolaska u četvrtfinale. Kroz treninge u Zagrebu gdje pokušat ćemo napraviti najbolju taktiku i sastav. Pozvali smo Pongračića, nije igrao za svoj klub, ali oporavio se od ozljede i potreban nam je još jedan stoper. Vidjet ćemo tijekom dana kako ćemo dalje kada se skupe svi”, istaknuo je Dalić.

O Bruni Petkoviću…

“Igrači u reprezentaciju dolaze s velikim poštovanjem, čast im je igrati u reprezentaciji. Nekad nisu najspremniji, tako je bilo s Brunom protiv Turske u Osijeku, bio je ozlijeđen, ali je želio igrati. To izuzetno cijenim, zato reprezentacija ima uspjehe, zbog takvih odnosa. Bruno je igrao protiv Škotske, zatim se protiv Poljske požalio na ozljedu. Doći će danas, razgovarat ćemo s njim i liječnicima. Donijeti ću odluku koja će, u prvom redu, biti najbolja za igrača, Dinamo i reprezentaciju. Ozlijeđen je, ne trenira, ali mi nije jasno zašto igra, to me smeta. Zajec me zvao, rekao sam mu da igrač mora doći na okupljanje, pa ćemo donijeti dobru odluku. Nije potrebna nervoza, komentari. Donijet ću najbolju odluku. To je sve što imam reći, nije potrebna nikakva nervoza oko toga”.

O napadačima…

“Ako se dogodi što u idućih dan, dva, reagirat ćemo s napadačima. Zasad su Kramarić, Matanović i Budimir dovoljni. Ivušić ima privatnih problema pa to rješava. Imamo na popisu četiri reprezentativna vratara, dobro smo popunjeni na toj poziciji”.

O Sandru Kulenoviću…

“Doveo se u krug naših najboljih opcija, igra dobro, ako ovako nastavi, jako brzo će doći u krug reprezentacije. Najvažnije je da je u dobroj formi, pratimo ga, samo tako neka nastavi. Imali smo odluku prije dva tjedna o napadačima, vjerujem njima”.

O zadnjoj liniji…

“Obrana? Šutalo je zdrav, jučer je odradio utakmicu i igrao je dobro. Ranije se odmarao zbog preventive. Šutalo, Gvardiol i Ćaleta-Car su naše opcije. Zvali smo Pongračića da imamo dodatnu opciju. Želimo u Škotskoj biti agresivni i odraditi posao. Zanimljivo, od toliko stopera smo ostali samo na njima. Imamo dobar roster da možemo kombinirati. Nemamo standardnost, ali nadam se da ćemo do ljeta to dobiti. Žao mi je da ne igraju u klubovima, meni nije svojstveno da zovem one koji ne igraju, ali nadam se da će i to doći”.

O Mislavu Oršiću…

“Vratio se nakon ozljede, došao je u dobru formu, došlo je do promjene trenera koji ga je otpisao. Kad smo radili popis, Sosa je bio ozlijeđen i ono što sam vidio od Mislava, bio je u dobroj formi i dobro je trenirao. Dalo mi je to za pravo da vidim da je Orša jedna od najboljih alternativa na lijevoj strani ako igram s tri stopera. Zato je dobio poziv. Sosa je bio ozlijeđen, razgovarali smo i rekao mi je da ga je trener maknuo iz momčadi, nije više u konkurenciji. Morat će tražiti novi klub ako želi ostati u krugu reprezentacije. Situacija nije sjajna, mora donijeti odluku. Bit će s nama”.

O Ivanu Perišiću i Poljudu…

“Nećemo o tome razmišljati, stavit ćemo u momčad najbolje što imamo. Puno puta sam govorio tko je i što je Ivan Perišić, što je sve dao za hrvatski nogomet, bilo bi nelogično da doživi neugodan doček. Mislim da zaslužuje respekt svih nas”.

O Luki Ivanušecu i pretpozivima…

“Pretpoziv je u biti osiguranje nama da klub mora pustiti igrača ako se nešto nepredviđeno dogodi. To nam služi kao alternativa. Ivanušec je isto imao lošiju situaciju u klubu pa sad ne igra. Odlučio sam da ovog puta ne dođe. Pretpoziv je nama dobar, ne vidim alternativu”.

Čast zaključiti konferenciju za medije dobio je Vili Kero, učenik osmog razreda Osnovne škole Kralj Tomislav u Zagrebu, koji se svesrdno trudi jednog dana postati sportski novinar. Ovo je bilo njegovo pitanje upućeno Zlatku Daliću:

Jeste li razgovarali s igračima kako zatvarati utakmicu kad vodimo jer smo u posljednje vrijeme primali golove u zadnjim trenucima i tako ostajali bez pobjeda?

“Vili, dobrodošao na konferenciju za medije. Razgovaramo stalno o tome jer je riječ o problemu koji nam se stalno događa, pogotovo u zadnjim utakmicama. Primali smo golove u zadnjim sekundama što je teško objašnjivo. Dođe do pada koncentracije, do opuštanja i protivnik kazni našu svaku pogrešku. Moramo na tome raditi i o tome razgovarati, nepotrebno je da se kao momčad povučemo i branimo u šesnaestercu. To nam se dogodilo i protiv Škotske, u tom razdoblju moramo preuzeti još veću odgovornost i napasti visoko. Napad je najbolja obrana. A tebi hvala na pitanju, želim ti svu sreću u daljnjem školovanju i budućem poslu”.

Stadion u Kranjčevićevoj u siječnju 2025. godine ide u temeljitu obnovu, a nova verzija koštat će oko 30 milijuna eura. Sve bi trebalo biti gotovo 2026. godine

Zagreb će konačno dobiti stadion kakav zaslužuje.

Već godinama najavljuje se obnova stadiona u Kranjčevićevoj ulici, rekonstrukcija je već trebala i započeti, završetak je bio najavljivan za proljeće 2025. godine, ali kako je to već uobičajeno u Hrvatskoj, nekoliko puta su se pomicali rokovi pa je konačan početak izgradnje najavljen za siječanj 2025. godine.

Liraglutide, a synthetic analog of the incretin hormone GLP-1 (glucagon-like peptide-1), is widely studied for its structural resemblance to endogenous peptides involved in metabolic regulation. With structural modifications supporting its stability and binding affinity, Liraglutide is believed to hold promising research value beyond its conventional fields.

This article explores speculative areas where Liraglutide’s biochemical characteristics might find relevance, such as cellular metabolism, lipid regulation, mitochondrial science, neurobiology, and cardiovascular science. By delving into the peptide’s interaction with cellular pathways, its possible modulation of metabolic responses, and its role in glucose homeostasis, we seek to outline its research potential across scientific domains, ultimately envisioning Liraglutide’s broader implications in the landscape of biomolecular research.

Introduction to Liraglutide’s Biochemistry and Molecular Structure

Liraglutide is structurally akin to GLP-1 but modified with a C16 acyl chain to support improved stability, making it more resistant to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This structural adaptation is believed to extend Liraglutide’s half-life, allowing it to maintain more prolonged receptor activity. Studies suggest that given these properties, Liraglutide represents a unique research tool for examining GLP-1 receptor-linked signaling in various cell types. Research indicates that its structure may support binding to lipid bilayers, creating possibilities for studies of receptor affinity and membrane permeability.

Cellular Metabolism and Mitochondrial Function

Investigations purport that the peptide’s impact on cellular metabolism is a compelling area of interest. By stimulating GLP-1 receptors, Liraglutide is theorized to modulate intracellular signaling pathways associated with ATP production and mitochondrial biogenesis. Research suggests that the peptide may support mitochondrial efficiency, potentially supporting cellular energy production and ATP turnover rates. Studies have indicated that Liraglutide might encourage better-supported mitochondrial respiration in muscle cells and liver cells, suggesting avenues for research into age-related declines in mitochondrial function and metabolic disorders.

Additionally, the peptide seems to influence pathways related to oxidative stress, a key factor in mitochondrial dysfunction. Investigations purport that GLP-1 receptor agonists, including Liraglutide, may exert an antioxidative impact by reducing reactive oxygen species (ROS) production. This property might be explored in studies examining cellular resilience to oxidative stress, especially within cell models subjected to metabolic insults or environmental toxins.

Lipid Metabolism and Its Implications in Liver Integrity

Liraglutide’s potential to impact lipid metabolism has sparked interest in hepatic research. Investigations purport that the peptide might influence lipid synthesis and transport, and its action on GLP-1 receptors may be critical for understanding lipid regulation within hepatocytes. Research indicates that Liraglutide might reduce lipid accumulation in liver cells, a factor highly relevant to the study of non-alcoholic fatty liver disease (NAFLD) and other hepatic disorders. Investigations in this area suggest that Liraglutide may inhibit de novo lipogenesis (DNL) while supporting fatty acid oxidation, creating a dual action relevant to lipid homeostasis in hepatocytes.

Liraglutide in Cognitive and Neuronal Research

Beyond metabolic research, Liraglutide’s activity on GLP-1 receptors in the central nervous system has prompted interest in its potential neuroprotective properties. Research suggests that Liraglutide may influence neurogenesis and cognitive processes through GLP-1 receptor activation within the brain. This receptor distribution in brain regions linked to learning, memory, and neuroplasticity positions Liraglutide as a potential agent for investigating neurobiological pathways related to cognitive integrity.

In animal models, it has been hypothesized that Liraglutide might promote the survival of neuronal cells exposed to stressors, such as excitotoxic agents or amyloid-beta plaques, which are commonly associated with neurodegenerative processes. Liraglutide’s theoretical neurotrophic impacts might be an interesting focus for studies examining mechanisms of neuronal repair and resilience.

Cardiovascular Research: Vascular Function and Endothelial Integrity

Liraglutide’s potential impact on cardiovascular integrity is an emerging area of interest, particularly concerning its possible influence on vascular smooth muscle and endothelial function. Studies have indicated that GLP-1 receptor activity may play a role in vasodilation, theorized to be mediated by nitric oxide (NO) synthesis in endothelial cells. This property might render Liraglutide a valuable tool for studying vascular function, with implications for research into hypertension, arterial stiffness, and overall vascular integrity.

Another promising line of investigation is the peptide’s potential to modulate endothelial homeostasis. It is speculated that Liraglutide may reduce oxidative damage in endothelial cells, fostering an environment conducive to vascular integrity. Studies suggest that this potential antioxidative impact might be particularly helpful to researchers examining endothelial responses to hyperglycemia and inflammation, both of which are thought to impair vascular function. As endothelial integrity is critical in many cardiovascular conditions, Liraglutide’s influence on endothelial resilience and repair mechanisms may be a pivotal focus in cardiovascular research.

Liraglutide in Immunometabolism Research

An intriguing area of research involves Liraglutide’s potential role in immunometabolic regulation. As GLP-1 receptors are expressed in various immune cells, it is hypothesized that Liraglutide may affect immune function by modulating energy metabolism within immune cells. For example, certain studies suggest that Liraglutide may influence macrophage activity and polarization, which might prove to be instrumental in understanding immune responses in inflammatory conditions and metabolic disorders.

Conclusion: The Expansive Research Horizons of Liraglutide

Research indicates that the peptide Liraglutide, through its interaction with GLP-1 receptors, may reveal complex biological mechanisms across a broad range of scientific disciplines. From metabolic regulation and mitochondrial resilience to neurobiology and cardiovascular function, Liraglutide’s possible influence on GLP-1 pathways provides a promising scaffold for future research. By understanding Liraglutide’s biochemical interactions and signaling mechanisms, scientific investigations may uncover new insights into cellular function, energy metabolism, and immune modulation. Click here for the highest-quality Liraglutide.

References

[i] Drucker, D. J., Habener, J. F., & Holst, J. J. (2017). Discovery, characterization, and clinical development of the glucagon-like peptides. Journal of Clinical Investigation, 127(12), 4217–4227. https://doi.org/10.1172/JCI97233

[ii] Campbell, J. E., & Drucker, D. J. (2013). Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism, 17(6), 819-837. https://doi.org/10.1016/j.cmet.2013.04.008

[iii] Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2012). Blood-brain glucose transfer in Alzheimer’s disease: Effect of GLP-1 analog treatment. Scientific Reports, 2, 105. https://doi.org/10.1038/srep00105

[iv] Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., … & Zinman, B. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(19), 1834-1844. https://doi.org/10.1056/NEJMoa1607141

[v] Nauck, M. A., & Meier, J. J. (2019). Incretin hormones: Their role in health and disease. Diabetes, Obesity and Metabolism, 21(S1), 5-21. https://doi.org/10.1111/dom.13667